John Parkinson

A presenting author offers greater study insights into this novel therapy for the treatment of serious infections.

Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.

A prospective study looked at the association of contract nursing and SARS-CoV-2 outbreaks.

Investigators wanted to look at real world experiences with combination therapy in older people living with HIV.

Results from the Pivotal ADAPT-PO study were reported.

Results show medication provides therapeutic response for Candida.

In a large nursing home study, asymptomatic and symptomatic residents were found to carry similar viral loads.

A study looked at weight gain when changing therapy regimens.

The participant was taking a placebo and the trial will continue according to initial reports.

Sulopenem was superior to ciprofloxacin for the treatment of uncomplicated urinary tract infections.

In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.

Covaxx has developed its investigational vaccine and is currently in a phase 1/2 trial.

Data from a Phase 1/2 randomized controlled trial of vaccine candidate, BBIBP-CorV, is shown to be safe.

A letter signed by 80 researchers says the concept put forth by the Great Barrington Declaration is “a dangerous fallacy.”

Looking at certain characteristics in a blood test can help forecast patients’ course and inform clinicians’ determination on the course of treatment.

The company made the announcement Monday night.

The BioGX’s Xfree COVID-19 Direct RT-PCR test has the potential to increase testing capacity by millions per week.

New UK population study shows majority of those who test positive did not have typical symptoms associated with the virus.

Abbott’s IgM test offer high specificity and sensitivity 15 days after onset of symptoms.

Athersys has developed its MultiStem cell therapy for COVID-19 Acute respiratory distress syndrome (ARDS). Athersys CEO Gil Van Bokkelen, PhD, and CFO Ivor Macleod, recently spoke to Contagion providing background on the company and their MultiStem therapy.

RECOVERY trial reported hospitalized COVID-19 patients did not see a benefit compared to those patients who received usual care.

The President gave Regeneron’s therapy, REGN-COV2, a ringing endorsement Wednesday night and stated both companies’ therapies should be given for free to the public.

This further emphasizes the higher rate of mortality in COVID-19 compared to influenza.

Within NIH is the National Center for Advancing Translational Sciences (NCATS) and they will oversee the grant awards. Christopher Austin, MD, director, NCATS, discusses the specifics of the 2 trials being expanded.

Aethlon Medical is developing its proprietary Hemopurifier, which is a therapeutic device designed for the single use depletion of circulating viruses.

A study found that 14% of them experienced cardiac arrest within two weeks of being admitted to the ICU.

Principal investigator Richard Becker, MD, director of the University of Cincinnati Heart, Lung and Vascular Institute discusses the phase 2 clinical trial for razuprotafib.

Regeneron’s REGN-COV2 reduced the time to alleviate symptoms.

In a national survey, parents responded they would not be getting a vaccine for their kids during the COVID-19 pandemic.